Dr. Naamit K Gerber, MD
Claim this profileNew York University Medical Center
Studies Breast Cancer
Studies Cancer
6 reported clinical trials
12 drugs studied
Area of expertise
1Breast Cancer
Stage I
Stage II
HER2 negative
2Cancer
Affiliated Hospitals
Clinical Trials Naamit K Gerber, MD is currently running
Short-Course Radiation Therapy
for Breast Cancer
Breast-conserving surgery followed by re-irradiation with partial breast irradiation (rPBI) has recently been found to be a safe alternative to mastectomy for women who have undergone prior whole breast radiation. By reducing the volume of tissue receiving radiation, rPBI has been associated with less toxicity and improved cosmetic outcomes. For many women with early-stage breast cancer, shorter 1-week (5-fraction) courses of breast radiation (ultra-fractionation) have been found to be equivalent to longer fractionation schedules in the upfront treatment setting. These 1-week schedules are more convenient for patients, with fewer treatments and shorter overall treatment time. The investigators hypothesize that a 1-week ultra-hypofractionated rPBI regimen following breast-conserving surgery (BCS) for local recurrence or new primary breast cancer in the previously irradiated breast (LR) will be associated with acceptable toxicity at 1 year (\<13% grade \>3 toxicity).
Recruiting1 award N/A8 criteria
Omitting Radiation Therapy
for Breast Cancer
The purpose of this study is to compare the effects on low risk breast cancer receiving usual care that includes regional radiation therapy, with receiving no regional radiation therapy. Researchers want to see if not giving this type of radiation treatment works as well at preventing breast cancer from coming back.
Recruiting2 awards Phase 319 criteria
More about Naamit K Gerber, MD
Clinical Trial Related5 years of experience running clinical trials · Led 6 trials as a Principal Investigator · 3 Active Clinical TrialsTreatments Naamit K Gerber, MD has experience with
- Radiation
- PBI Radiotherapy 6 Gy
- PBI Radiotherapy 8 Gy
- Caffeine Anhydrous 5% Added To Lipoderm Cream Base
- Lipoderm Cream Base
- Linac Based VMAT TBI
Breakdown of trials Naamit K Gerber, MD has run
Breast Cancer
Hematologic Malignancies
Blood Cancers
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Naamit K Gerber, MD specialize in?
Naamit K Gerber, MD focuses on Breast Cancer and Cancer. In particular, much of their work with Breast Cancer has involved Stage I patients, or patients who are Stage II.
Is Naamit K Gerber, MD currently recruiting for clinical trials?
Yes, Naamit K Gerber, MD is currently recruiting for 3 clinical trials in New York New York. If you're interested in participating, you should apply.
Are there any treatments that Naamit K Gerber, MD has studied deeply?
Yes, Naamit K Gerber, MD has studied treatments such as Radiation, PBI Radiotherapy 6 Gy, PBI Radiotherapy 8 Gy.
What is the best way to schedule an appointment with Naamit K Gerber, MD?
Apply for one of the trials that Naamit K Gerber, MD is conducting.
What is the office address of Naamit K Gerber, MD?
The office of Naamit K Gerber, MD is located at: New York University Medical Center, New York, New York 10016 United States. This is the address for their practice at the New York University Medical Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.